Safety, tolerability, and dosing of IY-828026 in healthy adults
Official title: A Randomized, Double-blinded, Partial-open, Placebo/Active-controlled, Single/Multiple Dosing, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Characteristics of IY-828026 in Healthy Adult Volunteers
Run by Il-Yang Pharm. Co., Ltd. · NCT07433556 · Data updated 2026-11-12
This test tries to see how safe and well-tolerated IY-828026 is and how the body absorbs and clears it in healthy adults aged 19 to 50.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 19 Years to 50 Years |
| Sex | All |
| Enrollment | 86 (estimated) |
| Sponsor | Il-Yang Pharm. Co., Ltd. Industry-sponsored |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | March 23, 2026 |
| Main results expected | March 2027 |
| Study ends | June 2027 |
| Registry record updated | March 27, 2026 |
| Trial ID | NCT07433556 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged 19–50 years with BMI 18.5–29.9 kg/m2 and body weight 50–90 kg who can provide informed consent and attend clinic visits are ideal candidates.
✕Probably not a fit
Individuals with significant hepatic, renal, cardiac, psychiatric, or other major medical conditions, recent H. pylori treatment/positive test, known hypersensitivity to related drugs, pregnancy, or who fall outside the specified age/weight/BMI ranges are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, double-blinded, partially open, placebo- and active-controlled Phase 1 dose-escalation study enrolls healthy adult volunteers to characterize safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD). Participants receive single and multiple escalating doses of IY-828026 or matching controls with planned safety monitoring between cohorts. Serial blood and possibly other samples will be collected to define absorption, distribution, metabolism, elimination, and PD markers. Findings will inform safe dosing and monitoring for subsequent patient-focused trials.
Why it matters
Potential benefit: If successful, the trial could establish a safe dosing range and PK/PD profile that enables later patient trials and supports future therapeutic development.
How similar studies have gone: Phase 1 dose-escalation PK/PD studies of similar small-molecule agents commonly establish safety and dosing for later phases, but IY-828026 itself is novel and its human effects are untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy adult volunteers aged ≥ 19 and ≤ 50 years at screening * Body weight ≥ 50.0 kg to ≤ 90.0 kg and body mass index (BMI) of ≥ 18.5 kg/m2 to ≤ 29.9 kg/m2 at screening * Volunteers who were fully informed of and completely understood this study, voluntarily agreed to participate, and provided written consent to comply with the precautions Exclusion Criteria: * Current or history of clinically significant disease of hepatobiliary (severe hepatic impairment, viral hepatitis, etc.), renal (severe renal impairment, etc.), nervous, immune, respiratory, gastrointestinal, endocrine, hemato-oncologic, cardiovascular (heart failure, torsades de pointes, etc.), urinary, or psychiatric (mood disorder, obsessive compulsory disorder, etc.) system or sexual dysfunctions * H. pylori eradication treatment within 6 months or positive result for H. pylori at screening * Hypersensitivity or history of clinically significant hypersensitivity to PPIs, P-CABs, and other drugs (aspirin, antibiotics, etc.) * A positive result in serology (hepatitis B tests, hepatitis C tests, human immunodeficiency virus \[HIV\] tests, or syphilis tests) * History of drug abuse or positive results for drug abuse in the urine drug screen
Where it's running
-
Seoul National University Hospital
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: YunSeon Kim
- Email: yskim@ilyang.co.kr
- Phone: 82-70-7165-7319
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Oral OT and AVP Effects on Attention to Emotional Faces in Healthy Adults
This study tests whether 24 IU of oxytocin or 24 IU of vasopressin, given as an oral spray/lollipop, change how healthy adults pay attention to emotional faces compared with a placebo.
-
Chewing and Eating Rate Linked to Weight in Children
This study tests how chewing, eating speed, and ghrelin levels relate to body weight in healthy kids aged 6–11.
-
Remediation of memory impairments using motor encoding and dynamic imagery in Alzheimer’s disease
This trial tests whether combining real action, motor imagery, and dynamic video cues can help memory in people with early Alzheimer’s disease and compares it to a control group without Alzheimer’s.
-
How body composition may affect drug absorption and metabolism
This observational study tests whether body composition influences how drugs are absorbed, distributed, and metabolized in healthy volunteers.
-
Safety and food-effect testing of HSK55879 tablets in healthy adults
This will test whether HSK55879 tablets are safe, well tolerated, and how food affects their absorption in healthy adults aged 18–45.
-
MDMA for short-term reduction of experimentally induced pain in healthy adults
The researchers will test whether single oral doses of MDMA reduce experimentally induced acute pain, hyperalgesia, and allodynia in healthy adult volunteers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.